Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin for preventing and treating COVID-19

Popp et al., Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD015017.pub2
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
This meta analysis is designed to exclude most studies. Authors select a small subset of studies, with a majority of results based on only 1 or 2 studies. Authors split up studies which dilutes the effects and results in a lack of statistical significance for most outcomes. Authors perform 16+ meta analyses with very few studies in each analysis, and do not combine the evidence from all studies. However, we can consider the probability of the observed results across all outcomes.
Authors find positive results for 11 of 12 primary efficacy outcomes with events, or 16 of 18 including secondary outcomes. One of the primary outcomes and two of the secondary outcomes show statistically significant improvements in isolation. If we assume independence, the probability that 11+ of 12 primary efficacy outcomes were positive for an ineffective treatment is p = 0.003. For 16+ of 18 outcomes we get p = 0.0007. This simple analysis does not take into account the magnitude of positive effects, or the dependence due to some studies contributing multiple outcomes, however observation suggests that a full analysis of the combined evidence is likely to show efficacy.
The study is entirely retrospective in the current version. The protocol is dated April 20, 2021, and the most recent study included is from March 9, 2021. The protocol was modified after publication in order to include a close to null result (Beltran Gonzalez "patients discharged without respiratory deterioration or death at 28 days"), so the current protocol is dated July 28, 2021.
Authors excluded many studies by requiring results at a specific time, for example mortality, ventilation, etc. required results at exactly 28 days. Authors excluded all prophylaxis studies by requiring results at exactly 14 days.
Studies comparing with other medications were excluded, however these studies confirm efficacy of ivermectin. The only case where they could overstate the efficacy of ivermectin is if the other medication was harmful. There is some evidence of this for excessive dosage/very late stage use, however that does not apply to any of the studies here.
Studies using combined treatment were excluded, even when it is known that the other components have minimal or no effect. 3 of 4 RCTs with combined treatment use doxycycline in addition, which was shown to have no significant effect in Butler. Other studies were excluded by requiring PCR confirmation.
Authors are inconsistent regarding active comparators. They state that hydroxychloroquine “does not work”, yet excluded trials comparing ivermectin to a drug they hold to be inactive. On the other hand, remdesivir was an acceptable comparator, although it is considered to be effective standard of care in some locations3.
Authors fail to recognize that Risk of Bias (RoB) domains such as blinding are far less important for the objective outcome of mortality.
Authors include Beltran Gonzalez as "moderate" COVID-19, however patients in this study were in severe condition (baseline SatO2 83).
Fordham summarizes several problems:
unsupported assertions of adverse reactions to ivermectin, and the outdated claim that unsafe dosing would be needed to be effective;
a demand for PCR or antigen testing, without analysis of reliability and not universally available even in developed countries at the start of the pandemic;
contradictions in the exclusion criteria, including placebo and approved SoC comparators, but rejecting hydroxychloroquine, though held to be ineffective (and an approved SoC in some jurisdictions);
inclusion of “deemed active” comparators whilst excluding “potentially active” ones;
exclusion of combination therapies, though the norm among practising clinicians;
the rejection of other than RCTs when the objective is a “complete evidence profile”;
arbitrary time-points for outcome measures, excluding non-compliant trials;
fragmentation of data by location of care under varying hospitalisation criteria;
the resulting focus on a small fraction of the available clinical evidence, with most comparisons based on single studies with no meta-analysis possible;
a resulting inpatient mortality comparison with fewer patients than a June 2020 confounder-matched study;
no conclusion on the headline mortality outcome, when multiple lines of evidence from elsewhere (including the WHO) point to significant mortality advantage.
Cochrane was reputable in the past, but is now controlled by pharmaceutical interests. For example, see the news related to the expulsion of founder Dr. Gøtzsche and the associated mass resignation of board members in protest4-6. For another example of bias see ebm.bmj.com.
The BiRD group gave the following early comment: "Yesterday’s Cochrane review surprisingly doesn’t take a pragmatic approach comparing ivermectin versus no ivermectin, like in the majority of other existing reviews. It uses a granular approach similar to WHO’s and the flawed Roman et al paper, splitting studies up and thereby diluting effects. Consequently, the uncertain conclusions add nothing to the evidence base. A further obfuscation of the evidence on ivermectin and an example of research waste. Funding conflicts of interests of the authors and of the journal concerned should be examined."
For dicussion of issues added in the updated version see Popp.
Authors report funding from the German Federal Ministry of Education and Research, which may be influenced by9.
Bias due to funding is ignored for both analyzed studies and Cochrane. For Cochrane funders see10,11.
7 meta analyses show significant improvements with ivermectin for mortality12-17, hospitalization18, recovery14, and cases14.
Currently there are 104 ivermectin for COVID-19 studies, showing 48% lower mortality [35‑59%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 81% fewer cases [71‑87%].
Popp et al., 28 Jul 2021, preprint, 8 authors.
This PaperIvermectinAll
Ivermectin for preventing and treating COVID-19
Maria Popp, Miriam Stegemann, Maria-Inti Metzendorf, Susan Gould, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel
Cochrane Database of Systematic Reviews, doi:10.1002/14651858.cd015017.pub2
Analysis 1.2. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderate-to-severe COVID-19 treated in the inpatient setting, Outcome 2: Worsening of clinical status -need for invasive mechanical ventilation up to 28 days (primary analysis
CONSORT 2010 Statement Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine 2010;8:18. COVID Guidelines India 2021 Covid Management Guidelines India Group. COVID Management Guidelines India. indiacovidguidelines.org/ivermectin/ (accessed 15 May 2021). COVID-NMA Working Group COVID-NMA working group. The COVID-NMA initiative: a living mapping and living systematic review of Covid-19 trials. covidnma.com (accessed prior to 1 July 2021). Cochrane Library Trusted evidence. Informed decisions. Better health. Supplementary File_Ivermectin_Risk of Bias Weibel S, Popp M. Supplementary File_Ivermectin_Risk of Bias Excel Tool (Version 1). Zenodo 2021. • Inclusion criteria: aged 18-65 years; admitted to hospital within last 7 days; presence of fever (37.5 °C), cough, sore throat, or a combination; diagnosed positive for SARS-CoV-2 by rRT-PCR • Exclusion criteria: allergic to ivermectin or doxycycline, or if here was the potential for a drug-drug interaction with ivermectin or doxycycline; had chronic illnesses (e.g. ischaemic heart disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease); had received ivermectin or doxycycline (or both) in the last 7 days; were pregnant or lactating; or had participated in any other clinical trial within last month Interventions Cochrane Database of Systematic Reviews Study characteristics ..
References
Deeks, Higgins, Altman, Chapter 10: Analysing data and undertaking meta-analyses
Deng, Yin, Chen, Zeng, Clinical determinants for fatality of 44,672 patients with COVID-19, Critical Care, doi:10.1186/s13054-020-02902-w]Dong2020
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infectious Diseases, doi:10.1016/S1473-3099(20)30120-1
Dourmishev, Dourmishev, Schwartz, Ivermectin: pharmacology and application in dermatology, doi:10.1111/j.1365-4632.2004.02253
Garegnani, Madrid, Meza, Misleading clinical evidence and systematic reviews on ivermectin for COVID-19, BMJ Evidence Based Medicine
German Awmf Guideline, None
Goetz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of e icient nuclear vRNP import, Scientific Reports, doi:10.1038/srep23138
González-Canga, None
González-Canga, Sahagún-Prieto, Diez-Liébana, Fernández-Martínez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans, Journal of the American Association of Pharmaceutical Scientists, doi:10.1208/s12248-007-9000-9]Herrmann2020
Herrmann, Adam, Notz, Helmer, Sonntagbauer et al., COVID-19 induced acute respiratory distress syndrome -a multicenter observational study
Higgins, Lasserson, Chandler, Tovey, Thomas et al., Methodological Expectations of Cochrane Intervention Reviews
Hill, Abdulamir, Ahmed, Ashgar, Babalola et al., Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection, doi:10.21203/rs.3.rs-148845/v1
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, doi:10.1016/S0140-6736(20)30183-5
Inthout, Ioannidis, Rovers, Goeman, Plea for routinely presenting prediction intervals in meta-analysis, BMJ Open, doi:10.1136/bmjopen-2015-010247
Ivmmeta, com Ivermectin for COVID-19: real-time meta analysis of 60 studies
Karagiannidis, Mostert, Hentschker, Voshaar, Malzahn et al., Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study, Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30316-7
Kluge, Janssens, Welte, Weber-Carstens, Schälte et al., S3-Guideline -recommendations on Inpatient Treatment of Patients With COVID-19
Kobayashi, Jung, Linton, Kinoshita, Hayashi et al., Communicating the risk of death from novel coronavirus disease (COVID-19), Journal of Clinical Medicine, doi:10.3390/jcm9020580
Panahi, Poursaleh, Goldust, The e icacy of topical and oral ivermectin in the treatment of human scabies, Annals of Parasitology
Prescott, Girard, RECOVERY 2021 Recovery Collaborative Group. Dexamethasone in hospitalized patients with Covid-19, New England Journal of Medicine, doi:10.1001/jama.2020.14103
Rodríguez-Mega, Latin America's embrace of an unproven COVID treatment is hindering drug trials, Nature, doi:10.1038/d41586-020-02958-2]Schünemann2020
Rodríguez-Mega, None
Schünemann, Higgins, Vist, Glasziou, Akl et al., Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence
Siemieniuk, Rochwerg, Agoritsas, Lamontagne, Leo et al., A living WHO guideline on drugs for Covid-19, BMJ, doi:10.1136/bmj.m3379
Singh, Ryan, Kredo, Chaplin, Fletcher, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD013587.pub2
Sterne, Savović, Page, Elbers, Blencowe et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ, doi:10.1136/bmj.l4898
{ 'indexed': {'date-parts': [[2024, 4, 23]], 'date-time': '2024-04-23T16:51:43Z', 'timestamp': 1713891103957}, 'update-to': [ { 'updated': { 'date-parts': [[2021, 7, 28]], 'date-time': '2021-07-28T00:00:00Z', 'timestamp': 1627430400000}, 'DOI': '10.1002/14651858.cd015017', 'type': 'new_version', 'label': 'New version'}], 'reference-count': 212, 'publisher': 'Wiley', 'issue': '10', 'content-domain': {'domain': ['wiley.com', 'cochranelibrary.com'], 'crossmark-restriction': True}, 'DOI': '10.1002/14651858.cd015017.pub2', 'type': 'journal-article', 'created': {'date-parts': [[2021, 7, 28]], 'date-time': '2021-07-28T09:57:55Z', 'timestamp': 1627466275000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 51, 'title': 'Ivermectin for preventing and treating COVID-19', 'prefix': '10.1002', 'volume': '2021', 'author': [ { 'given': 'Maria', 'family': 'Popp', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anaesthesiology, Intensive Care, Emergency and ' 'Pain Medicine; University Hospital Wuerzburg; Wuerzburg ' 'Germany'}]}, { 'given': 'Miriam', 'family': 'Stegemann', 'sequence': 'additional', 'affiliation': [{'name': 'Germany'}]}, { 'given': 'Maria-Inti', 'family': 'Metzendorf', 'sequence': 'additional', 'affiliation': [{'name': 'Germany'}]}, { 'given': 'Susan', 'family': 'Gould', 'sequence': 'additional', 'affiliation': [{'name': 'Royal Liverpool University Hospital; Liverpool UK'}]}, { 'given': 'Peter', 'family': 'Kranke', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anaesthesia and Critical Care; University of ' 'Würzburg; Würzburg Germany'}]}, { 'given': 'Patrick', 'family': 'Meybohm', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anaesthesiology, Intensive Care, Emergency and ' 'Pain Medicine; University Hospital Wuerzburg; Wuerzburg ' 'Germany'}]}, { 'given': 'Nicole', 'family': 'Skoetz', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Medicine and University Hospital Cologne, Department ' 'of Internal Medicine; Center for Integrated Oncology, University ' 'of Cologne; Cologne Germany'}]}, { 'given': 'Stephanie', 'family': 'Weibel', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anaesthesiology, Intensive Care, Emergency and ' 'Pain Medicine; University Hospital Wuerzburg; Wuerzburg ' 'Germany'}]}], 'member': '311', 'published-online': {'date-parts': [[2021, 7, 28]]}, 'reference': [ { 'key': '10.1002/14651858.CD015017.pub2-BIB0001|cit1', 'doi-asserted-by': 'publisher', 'first-page': '214', 'DOI': '10.1016/j.ijid.2020.11.191', 'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may ' 'reduce the duration of illness', 'volume': '103', 'author': 'Ahmed', 'year': '2020', 'journal-title': 'International Journal of Infectious Diseases'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0002|cit2', 'unstructured': 'Chaccour C Casellas A Blanco-Di Matteo A Pineda I Fernandez-Montero A ' 'Ruiz-Castillo P The effect of early treatment with ivermectin on viral ' 'load, symptoms and humoral response in patients with mild COVID-19: a ' 'pilot, double-blind, placebo-controlled, randomized clinical trial ' 'researchsquare.com/article/rs-116547/v1 10.21203/rs.3.rs-116547/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0003|cit3', 'doi-asserted-by': 'crossref', 'first-page': '100720', 'DOI': '10.1016/j.eclinm.2020.100720', 'article-title': 'The effect of early treatment with ivermectin on viral load, symptoms ' 'and humoral response in patients with non-severe COVID-19: a pilot, ' 'double-blind, placebo-controlled, randomized clinical trial', 'volume': '32', 'author': 'Chaccour', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'issue': '1', 'key': '10.1002/14651858.CD015017.pub2-BIB0004|cit4', 'doi-asserted-by': 'crossref', 'first-page': '498', 'DOI': '10.1186/s13063-020-04421-z', 'article-title': 'The SARS-CoV-2 ivermectin Navarra-ISGlobal Trial (SAINT) to evaluate ' 'the potential of ivermectin to reduce COVID-19 transmission in low ' 'risk, non-severe COVID-19 patients in the first 48 hours after symptoms ' 'onset: a structured summary of a study protocol for a randomized ' 'control pilot trial', 'volume': '21', 'author': 'Chaccour', 'year': '2020', 'journal-title': 'Trials'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0005|cit5', 'unstructured': 'Pilot study to evaluate the potential of ivermectin to reduce COVID-19 ' 'transmission ' 'www.clinicaltrialsregister.eu/ctr-search/trial/2020-001474-29/ES'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0006|cit6', 'unstructured': 'Sars-CoV-2/COVID-19 ivermectin Navarra-ISGlobal Trial (SAINT) ' 'clinicaltrials.gov/ct2/show/NCT04390022'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0007|cit7', 'doi-asserted-by': 'publisher', 'first-page': '31', 'DOI': '10.18483/ijSci.2378', 'article-title': 'Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients', 'volume': '9', 'author': 'Chachar', 'year': '2020', 'journal-title': 'International Journal of Sciences'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0008|cit8', 'unstructured': 'Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients ' 'clinicaltrials.gov/ct2/show/NCT04739410'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0009|cit9', 'doi-asserted-by': 'crossref', 'unstructured': 'Gonzalez BJ González Gámez M Enciso EA Maldonado RJ Palacios HP Dueñas ' 'Campos S Efficacy and safety of ivermectin and hydroxychloroquine in ' 'patients with severe COVID-19. A randomized controlled trial ' 'medrxiv.org/content/early/2021/02/23/2021.02.18.21252037 ' '10.1101/2021.02.18.21252037', 'DOI': '10.1101/2021.02.18.21252037'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0010|cit10', 'unstructured': 'Hydroxychloroquine and ivermectin for the treatment of COVID-19 ' 'infection clinicaltrials.gov/ct2/show/NCT04391127'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0011|cit11', 'unstructured': 'Ivermectin as a possible treatment for COVID-19 ' "ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=46660&EncHid=&modid=&compid=','46660det'"}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0012|cit12', 'unstructured': 'Kirti R Roy R Pattadar C Raj R Agarwal N Biswas B Ivermectin as a ' 'potential treatment for mild to moderate COVID-19 - a double blind ' 'randomized placebo-controlled trial ' 'medrxiv.org/content/10.1101/2021.01.05.21249310v1 ' '10.1101/2021.01.05.21249310'}, { 'issue': '8', 'key': '10.1002/14651858.CD015017.pub2-BIB0013|cit13', 'doi-asserted-by': 'publisher', 'first-page': '4801859', 'DOI': '10.36106/paripex/4801859', 'article-title': 'Ivermectin as adjuvant to hydroxychlorquine in patients resistant to ' 'standard treatment for SARS-CoV-2: results of an open-label randomized ' 'clinical study', 'volume': '9', 'author': 'Kishoria', 'year': '2020', 'journal-title': 'Paripex - Indian Journal of Research'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0014|cit14', 'unstructured': 'Krolewiecki A Lifschitz A Moragas M Travacio M Valentini R Alonso D ' 'Antiviral effect of high-dose ivermectin in adults with COVID-19: a ' 'pilot randomised, controlled, open label, multicentre trial ' 'ssrn.com/abstract=3714649 10.2139/ssrn.3714649'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0015|cit15', 'unstructured': 'Ivermectin effect on SARS-CoV-2 replication in patients with COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04381884'}, { 'issue': '14', 'key': '10.1002/14651858.CD015017.pub2-BIB0016|cit16', 'doi-asserted-by': 'publisher', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19: a randomized clinical trial', 'volume': '325', 'author': 'López-Medina', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0017|cit17', 'unstructured': 'Efficacy of ivermectin in adult patients with early stages of COVID-19 ' '(EPIC Trial) (EPIC) clinicaltrials.gov/ct2/show/NCT04405843'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0018|cit18', 'unstructured': 'Ivermectin in COVID ' 'ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=44196&EncHid=&modid=&compid=%27,%2744196det%27'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0019|cit19', 'unstructured': 'Mohan A Tiwari P Suri T Mittal S Patel A Jain A Ivermectin in mild and ' 'moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial ' 'researchsquare.com/article/rs-191648/v1 10.21203/rs.3.rs-191648/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0020|cit20', 'unstructured': 'Ivermectin for severe COVID-19 management ' 'clinicaltrials.gov/ct2/show/NCT04646109'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0021|cit21', 'doi-asserted-by': 'publisher', 'first-page': '411', 'DOI': '10.1186/s12879-021-06104-9', 'article-title': 'Evaluation of the effectiveness and safety of adding ivermectin to ' 'treatment in severe COVID-19 patients', 'volume': '21', 'author': 'Okumuş', 'year': '2021', 'journal-title': 'BMC Infectious Diseases'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0022|cit22', 'unstructured': 'Okumuş N Demirtürk N Çetinkaya RA Güner R Avcı IY Orhan S Evaluation of ' 'the effectiveness and safety of adding ivermectin to treatment in severe ' 'COVID-19 patients researchsquare.com/article/rs-224203/v1 ' '10.21203/rs.3.rs-224203/v1'}, { 'issue': '2', 'key': '10.1002/14651858.CD015017.pub2-BIB0023|cit23', 'doi-asserted-by': 'crossref', 'first-page': '11', 'DOI': '10.3329/imcjms.v14i2.52826', 'article-title': 'Outcome of ivermectin treated mild to moderate COVID-19 cases: a ' 'single-centre, open-label, randomised controlled study', 'volume': '14', 'author': 'Podder', 'year': '2020', 'journal-title': 'IMC Journal of Medical Science'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0024|cit24', 'unstructured': 'A study to compare the efficacy and safety of different doses of ' 'ivermectin for COVID-19 clinicaltrials.gov/ct2/show/NCT04431466'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0025|cit25', 'doi-asserted-by': 'publisher', 'first-page': '505', 'DOI': '10.1016/j.toxrep.2021.03.003', 'article-title': 'Use of ivermectin in the treatment of Covid-19: a pilot trial', 'volume': '8', 'author': 'Pott-Junior', 'year': '2021', 'journal-title': 'Toxicology Reports'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0026|cit26', 'unstructured': 'Efficacy of ivermectin in COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04392713'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0027|cit27', 'doi-asserted-by': 'crossref', 'unstructured': 'Shah Bukhari KH Asghar A Perveen N Hayat A Mangat SA Butt KR Efficacy of ' 'ivermectin in COVID-19 patients with mild to moderate disease ' 'medrxiv.org/content/early/2021/02/05/2021.02.02.21250840 ' '10.1101/2021.02.02.21250840', 'DOI': '10.1101/2021.02.02.21250840'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0028|cit28', 'unstructured': 'Prophylactic ivermectin in COVID-19 contacts ' 'clinicaltrials.gov/ct2/show/NCT04422561'}, { 'issue': '2', 'key': '10.1002/14651858.CD015017.pub2-BIB0029|cit29', 'doi-asserted-by': 'publisher', 'first-page': '27', 'DOI': '10.7860/JCDR/2021/46795.14529', 'article-title': 'Use of ivermectin as a potential chemoprophylaxis for COVID-19 in ' 'Egypt: a randomized clinical trial', 'volume': '15', 'author': 'Shoumann', 'year': '2021', 'journal-title': 'Journal of Clinical and Diagnostic Research'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0030|cit30', 'unstructured': 'Babalola OE Bode CO \xa0Ajayi AA \xa0Alakaloko FM Otrofanowei E ' 'Ivermectin shows clinical benefits in mild to moderate COVID19: a ' 'randomised controlled double-blind, dose-response study in Lagos ' 'Quarterly Journal of Medicine 10.1093/qjmed/hcab035'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0031|cit31', 'doi-asserted-by': 'crossref', 'unstructured': 'Babalola OE Bode CO \xa0Ajayi AA \xa0Alakaloko FM Otrofanowei E ' 'Ivermectin shows clinical benefits in mild to moderate COVID19: a ' 'randomised controlled double blind dose response study in Lagos ' 'medrxiv.org/content/10.1101/2021.01.05.21249131v1 ' '10.1101/2021.01.05.21249131', 'DOI': '10.1101/2021.01.05.21249131'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0032|cit32', 'unstructured': 'Does ivermectin cure and/or prevent COVID-19? isrctn.com/ISRCTN40302986 ' '10.1186/ISRCTN40302986'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0033|cit33', 'doi-asserted-by': 'crossref', 'unstructured': 'Behera P Patro BK Singh AK Chandanshive PD Ravi K Pradhan SK Role of ' 'ivermectin in the prevention of COVID-19 infection among healthcare ' 'workers in India: a matched case-control study ' '10.1101/2020.10.29.20222661 10.1101/2020.10.29.20222661', 'DOI': '10.1101/2020.10.29.20222661'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0034|cit34', 'unstructured': 'Goren A \xa0Wambier CG McCoy J Early COVID-19 therapy with azithromycin ' 'plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient ' 'settings significantly reduced symptoms compared to known outcomes in ' 'untreated patients medrxiv.org/content/10.1101/2020.10.31.20223883v1 ' '10.1101/2020.10.31.20223883'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0035|cit35', 'unstructured': 'Cadegiani F \xa0Wambier CG Goren A McCoy J Early COVID-19 therapy with ' 'azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in ' 'outpatient settings significantly reduced symptoms compared to known ' 'outcomes in untreated patients researchsquare.com/article/rs-100994/v1 ' '10.21203/rs.3.rs-100994/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0036|cit36', 'unstructured': 'Cadegiani F Goren A McCoy J \xa0Wambier CG Hydroxychloroquine, ' 'nitazoxanide and ivermectin have similar effects in early COVID-19: a\xa0' 'head-to-head\xa0comparison of the Pre-AndroCoV Trial ' 'researchsquare.com/article/rs-98106/v1 10.21203/rs.3.rs-98106/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0037|cit37', 'doi-asserted-by': 'crossref', 'unstructured': 'Cadegiani F Goren A Wambier CG McCoy J An open-label prospective ' 'observational study of antiandrogen and non-antiandrogen early ' 'pharmacological approaches in females with mild-to-moderate COVID-19. ' 'The Pre-AndroCoV Female Trial ' 'medrxiv.org/content/10.1101/2020.10.05.20206870v1 ' '10.1101/2020.10.05.20206870', 'DOI': '10.1101/2020.10.05.20206870'}, { 'issue': '11', 'key': '10.1002/14651858.CD015017.pub2-BIB0038|cit38', 'doi-asserted-by': 'publisher', 'first-page': 'e024218', 'DOI': '10.1371/journal.pone.0242184', 'article-title': 'Lack of efficacy of standard doses of ivermectin in severe COVID-19 ' 'patients', 'volume': '15', 'author': 'Camprubi', 'year': '2020', 'journal-title': 'PloS\xa0One'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0039|cit39', 'unstructured': 'Carvallo H Hirsch R Safety and efficacy of the combined use of ' 'ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19 ' 'medrxiv.org/content/10.1101/2020.09.10.20191619v1 ' '10.1101/2020.09.10.20191619'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0040|cit40', 'unstructured': 'Ivermectin, aspirin, dexamethasone and enoxaparin as treatment of Covid ' '19 (IDEA) clinicaltrials.gov/ct2/show/NCT04425863'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0041|cit41', 'doi-asserted-by': 'crossref', 'unstructured': 'Chahla RE Medina Ruiz L Mena T Brepe Y Terranova P Ortega ES A ' 'randomized trial - intensive treatment based in ivermectin and ' 'iota-carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare ' 'agents medrxiv.org/content/10.1101/2021.03.26.21254398v1 ' '10.1101/2021.03.26.21254398v1', 'DOI': '10.1101/2021.03.26.21254398'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0042|cit42', 'unstructured': 'Prophylaxis Covid-19 in healthcare agents by intensive treatment with ' 'ivermectin and Iota-carrageenan (Ivercar-Tuc) ' 'clinicaltrials.gov/ct2/show/NCT04701710'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0043|cit43', 'unstructured': 'Chahla RE Medina Ruiz L Mena T Brepe Y Terranova P Ortega ES Cluster ' 'randomised trials - ivermectin repurposing for COVID-19 treatment of ' 'outpatients with mild disease In primary health care centers ' 'researchsquare.com/article/rs-495945/v1 10.21203/rs.3.rs-495945/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0044|cit44', 'doi-asserted-by': 'crossref', 'unstructured': 'Chahla RE Medina Ruiz L Mena T Brepe Y Terranova P Ortega ES Ivermectin ' 'reproposing for COVID-19 treatment outpatients in mild stage in primary ' 'health care centers medrxiv.org/content/10.1101/2021.03.29.21254554v1 ' '10.1101/2021.03.29.21254554v1', 'DOI': '10.1101/2021.03.29.21254554'}, { 'issue': '1', 'key': '10.1002/14651858.CD015017.pub2-BIB0045|cit45', 'doi-asserted-by': 'publisher', 'first-page': '63', 'DOI': '10.14744/ejmo.2021.16263', 'article-title': 'A comparative study on ivermectin-doxycycline and ' 'hydroxychloroquine-azithromycin therapy on COVID-19 patients', 'volume': '5', 'author': 'Chowdhury', 'year': '2021', 'journal-title': 'Eurasian Journal of Medicine and Oncology'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0046|cit46', 'unstructured': 'Chowdhury AT Islam J Dan G Shuixiang H A randomized trial of ' 'ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on ' 'COVID19 patients researchsquare.com/article/rs-38896/v1 ' '10.21203/rs.3.rs-38896/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0047|cit47', 'unstructured': 'A comparative study on ivermectin and hydroxychloroquine on the COVID19 ' 'patients in Bangladesh clinicaltrials.gov/ct2/show/NCT04434144'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0048|cit48', 'unstructured': 'Prophylactic ivermectin in COVID 19 contacts ' 'ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=46676&EncHid=&modid=&compid=%27,%2746676det%27'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0049|cit49', 'unstructured': 'Assessment of response of ivermectin on virological clearance in ' 'COVID-19 patients ' 'ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=46873&EncHid=&modid=&compid=%27,%2746873det%27'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0050|cit50', 'unstructured': 'A clinical study to assess the efficacy and safety of Tinefcon in ' 'patients with moderate COVID-19 infection ' 'cochranelibrary.com/es/central/doi/10.1002/central/CN-02186249/full'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0051|cit51', 'unstructured': 'Elgazzar A \xa0Youssef SA \xa0Hany B Efficacy and safety of ivermectin ' 'for treatment and prophylaxis of COVID-19 pandemic (preprint) ' 'researchsquare.com/article/rs-100956/v3 10.21203/rs.3.rs-100956/v3'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0052|cit52', 'unstructured': 'Efficacy and safety of ivermectin for treatment and prophylaxis of ' 'COVID-19 pandemic clinicaltrials.gov/ct2/show/NCT04668469'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0053|cit53', 'doi-asserted-by': 'crossref', 'unstructured': 'Melo dos Santos N Asato MS Moreira A Phase 2 randomized study on ' 'chloroquine, hydroxychloroquine or ivermectin in hospitalized patients ' 'with severe manifestations of SARS-CoV-2 infection Pathology Global ' 'Health 2021 115 4 235 42 10.1080/20477724.2021.1890887', 'DOI': '10.1080/20477724.2021.1890887'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0054|cit54', 'unstructured': 'The effect of chloroquine, hydroxychloroquine or ivermectin in patients ' 'with severe manifestations of coronavirus ' 'ensaiosclinicos.gov.br/rg/RBR-8h7q82/'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0055|cit55', 'doi-asserted-by': 'crossref', 'unstructured': 'Gorial FI \xa0Mashhadani S \xa0Sayaly HM \xa0Dakhil BD AlMashhadani ' 'MM \xa0Aljabory AM Effectiveness of ivermectin as add-on therapy in ' 'COVID-19 management (pilot trial) ' 'medrxiv.org/content/10.1101/2020.07.07.20145979v1 ' '10.1101/2020.07.07.20145979', 'DOI': '10.1101/2020.07.07.20145979'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0056|cit56', 'unstructured': 'Ivermectin adjuvant to hydroxychloroquin in COVID19 patients ' 'clinicaltrials.gov/ct2/show/NCT04343092'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0057|cit57', 'doi-asserted-by': 'crossref', 'unstructured': 'Hashim HA Maulood MF Rasheed AM \xa0Fatak DF Kabah KK \xa0Abdulamir AS ' 'Controlled randomized clinical trial on using Ivermectin with ' 'doxycycline for treating COVID-19 patients in Baghdad, Iraq ' 'medrxiv.org/content/10.1101/2020.10.26.20219345v1 ' '10.1101/2020.10.26.20219345', 'DOI': '10.1101/2020.10.26.20219345'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0058|cit58', 'unstructured': 'Effectiveness of ivermectin and doxycycline on COVID-19 patients ' 'clinicaltrials.gov/ct2/show/NCT04591600'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0059|cit59', 'unstructured': 'Evaluation of the effect of oral Ivermectin on the outcome of patients ' 'with COVID-19 and compare it with the effect of conjunctional therapies ' 'in patients admitted to Ziaeian, Baharloo, Imam Khomeini in the spring ' 'and summer 2020 en.irct.ir/trial/50305'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0060|cit60', 'unstructured': 'Determination the therapeutic effect of Ivermectin and Sovodak on ' 'patients infected with COVID-19: a clinical trial ' 'en.irct.ir/trial/51007'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0061|cit61', 'doi-asserted-by': 'publisher', 'first-page': '598', 'DOI': '10.1016/j.ijid.2021.02.014', 'article-title': 'Effectiveness of a multidrug therapy consisting of ivermectin, ' 'azithromycin, montelukast, and acetylsalicylic acid to prevent ' 'hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, ' 'Mexico', 'volume': '105', 'author': 'Lima-Morales', 'year': '2021', 'journal-title': 'International Journal of Infectious Diseases'}, { 'issue': '5', 'key': '10.1002/14651858.CD015017.pub2-BIB0062|cit62', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1177/03000605211013550', 'article-title': 'Ivermectin in combination with doxycycline for treating COVID-19 ' 'symptoms: a randomized trial', 'volume': '49', 'author': 'Mahmud', 'year': '2021', 'journal-title': 'Journal of International Medical Research'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0063|cit63', 'unstructured': 'Clinical trial of ivermectin plus doxycycline for the treatment of ' 'confirmed Covid-19 infection ' 'clinicaltrials.gov/ct2/show/results/NCT04523831'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0064|cit64', 'doi-asserted-by': 'crossref', 'unstructured': 'Morgenstern J Redondo JN De León A Canela JM Torres N Tavares J The use ' 'of compassionate Ivermectin in the management of symptomatic outpatients ' 'and hospitalized patients with clinical diagnosis of COVID-19 at the ' 'Medical Center Bournigal and the Medical Center Punta Cana, Rescue ' 'Group, Dominican Republic, from May 1 to August 10, 2020 ' 'medrxiv.org/content/10.1101/2020.10.29.20222505v1 ' '10.1101/2020.10.29.20222505', 'DOI': '10.1101/2020.10.29.20222505'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0065|cit65', 'unstructured': 'Remdesivir efficacy in coronavirus disease ' 'clinicaltrials.gov/ct2/show/NCT04345419'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0066|cit66', 'unstructured': 'Ivermectin and nitazoxanide combination therapy for COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04360356'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0067|cit67', 'unstructured': 'Trial to promote recovery from COVID-19 with ivermectin or endocrine ' 'therapy clinicaltrials.gov/ct2/show/NCT04374279'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0068|cit68', 'unstructured': 'Novel regimens in COVID-19 treatment ' 'clinicaltrials.gov/ct2/show/NCT04382846'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0069|cit69', 'unstructured': 'New antiviral drugs for treatment of COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04392427'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0070|cit70', 'unstructured': 'Ivermectin vs combined hydroxychloroquine and antiretroviral drugs (ART) ' 'among asymptomatic COVID-19 infection (IDRA-COVID19) ' 'clinicaltrials.gov/ct2/show/NCT04435587'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0071|cit71', 'unstructured': 'Early treatment with ivermectin and losartan for cancer patients with ' 'COVID-19 Infection clinicaltrials.gov/ct2/show/NCT04447235'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0072|cit72', 'unstructured': 'Trial of combination therapy to treat COVID-19 infection ' 'clinicaltrials.gov/ct2/show/NCT04482686'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0073|cit73', 'unstructured': 'Outpatient use of ivermectin in COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04530474'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0074|cit74', 'unstructured': 'Safety and efficacy of ivermectin and doxycycline in treatment of ' 'Covid-19 clinicaltrials.gov/ct2/show/NCT04551755'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0075|cit75', 'unstructured': 'Prevention and treatment for COVID -19 (severe acute respiratory ' 'syndrome coronavirus 2 SARS-CoV-2) associated severe pneumonia in the ' 'Gambia (PaTS-COVID) clinicaltrials.gov/ct2/show/NCT04703608'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0076|cit76', 'unstructured': 'Efficacy of nano-ivermectin impregnated masks in prevention of Covid-19 ' 'among healthy contacts and medical staff ' 'clinicaltrials.gov/ct2/show/NCT04723459'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0077|cit77', 'unstructured': 'Safety & efficacy of low dose aspirin/ivermectin combination therapy for ' 'treatment of Covid-19 patients (IVCOM) ' 'clinicaltrials.gov/ct2/show/NCT04768179'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0078|cit78', 'unstructured': 'Dose-finding study of Ivermectin treatment on patients infected with ' 'Covid-19: a clinical trial en.irct.ir/trial/47012'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0079|cit79', 'unstructured': 'Niaee MS Allami A Javadi A Ivermectin as an adjunct treatment for ' 'hospitalized adult COVID-19 patients: a randomized multi-center clinical ' 'trial (preprint) researchsquare.com/article/rs-109670/v1 ' '10.21203/rs.3.rs-109670/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0080|cit80', 'unstructured': 'Sherman MS Vogel F Sacks J ICON (Ivermectin in COvid Nineteen) study: ' 'use of ivermectin is associated with lower mortality in hospitalized ' 'patients with COVID19 medrxiv.org/content/10.1101/2020.06.06.20124461v2 ' '10.1101/2020.06.06.20124461'}, { 'issue': '1', 'key': '10.1002/14651858.CD015017.pub2-BIB0081|cit81', 'doi-asserted-by': 'publisher', 'first-page': '85', 'DOI': '10.1016/j.chest.2020.10.009', 'article-title': 'Use of ivermectin is associated with lower mortality in hospitalized ' 'patients with coronavirus disease 2019: the ivermectin in COVID ' 'nineteen study', 'volume': '159', 'author': 'Sherman', 'year': '2021', 'journal-title': 'Chest'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0082|cit82', 'unstructured': 'A preventive treatment for migrant workers at high-risk of COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04446104'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0083|cit83', 'doi-asserted-by': 'publisher', 'first-page': '314', 'DOI': '10.1016/j.ijid.2021.04.035', 'article-title': 'Positive impact of oral hydroxychloroquine and povidone-iodine throat ' 'spray for COVID-19 prophylaxis: an open-label randomized trial', 'volume': '106', 'author': 'Seet', 'year': '2021', 'journal-title': 'International Journal of Infectious Diseases'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0084|cit84', 'unstructured': 'Effectiveness of ivermectin in the treatment of coronavirus infection in ' 'patients admitted to educational hospitals of Mazandaran in 2020 ' 'en.irct.ir/trial/49174'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0085|cit85', 'unstructured': 'Effects of ivermectin in patients with COVID-19: a multicenter, ' 'double-blind, randomized, controlled clinical trial Clinical ' 'Therapeutics 10.1016/j.clinthera.2021.04.007'}, { 'issue': '10', 'key': '10.1002/14651858.CD015017.pub2-BIB0086|cit86', 'first-page': '177', 'article-title': 'Utility of ivermectin and doxycycline combination for the treatment of ' 'SARS-CoV-2', 'volume': '7', 'author': 'Sasank', 'year': '2020', 'journal-title': 'International Archives of Integrated Medicine'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0087|cit87', 'unstructured': 'Pragmatic study "CORIVER": ivermectin as antiviral treatment for ' 'patients infected by SARS-COV2 (COVID19) ' 'clinicaltrialsregister.eu/ctr-search/trial/2020-001971-33/ES'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0088|cit88', 'unstructured': 'Multicenter, randomized, double-blind, placebo-controlled study ' 'investigating efficacy, safety and tolerability of ivermectin HUVE-19 in ' 'patients with proven SARS-CoV-2 infection (COVID-19) and manifested ' 'clinical symptoms ' 'clinicaltrialsregister.eu/ctr-search/trial/2020-002091-12/BG'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0089|cit89', 'unstructured': 'A clinical trial to study the effects of hydroxychloroquine, ciclesonide ' 'and ivermectin in treatment of moderate COVID-19 illness ' 'ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43364'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0090|cit90', 'unstructured': 'To study effect of ivermectin drug in patients infected with SARS-CoV-2 ' 'virus ' 'ctri.nic.in/Clinicaltrials/showallp.php?mid1=44373&EncHid=&userName=CTRI/2020/06/025960'}, { 'issue': '5', 'key': '10.1002/14651858.CD015017.pub2-BIB0091|cit91', 'doi-asserted-by': 'publisher', 'first-page': '737', 'DOI': '10.29309/TPMJ/2021.28.05.5867', 'article-title': 'Potential use of azithromycin alone and in combination with ivermectin ' 'in fighting against the symptoms of COVID-19', 'volume': '28', 'author': 'Faisal', 'year': '2020', 'journal-title': 'Professional Medical Journal\xa0'}, { 'issue': '1', 'key': '10.1002/14651858.CD015017.pub2-BIB0092|cit92', 'doi-asserted-by': 'publisher', 'first-page': '4', 'DOI': '10.1186/s13063-020-04988-7', 'article-title': 'The efficacy and safety of ivermectin in patients with mild and ' 'moderate COVID-19: a structured summary of a study protocol for a ' 'randomized controlled trial', 'volume': '22', 'author': 'Hosseini', 'year': '2021', 'journal-title': 'Trials'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0093|cit93', 'unstructured': 'The efficacy and safety of Ivermectin in patients with COVID-19: a ' 'randomized clinical trial en.irct.ir/trial/49501'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0094|cit94', 'unstructured': 'Evaluation of the effect of ivermectin in hospitalized patients with ' 'COVID-19 in Imam Reza Hospital in Mashhad en.irct.ir/trial/49180'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0095|cit95', 'unstructured': 'Evaluation of prophylaxis induced by ivermectin in populations exposed ' 'to COVID-19 patients www.irct.ir/trial/51999'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0096|cit96', 'unstructured': 'Clinical trial study of the therapeutic effect of ivermectin, besides ' 'kaletra and chloroquine in patients with coronavirus disease 2019 ' '(COVID-19) en.irct.ir/trial/48444'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0097|cit97', 'unstructured': 'Study on the effects of using ivermectin to prevent COVID-19 in an adult ' 'population in Brazil www.isrctn.com/ISRCTN90437126'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0098|cit98', 'unstructured': 'The efficacy of ivermectin in larger doses in COVID-19 treatment ' 'clinicaltrials.gov/ct2/show/NCT04351347'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0099|cit99', 'unstructured': 'Novel agents for treatment of high-risk COVID-19 positive patients ' 'clinicaltrials.gov/ct2/show/NCT04374019'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0100|cit100', 'unstructured': 'Efficacy and safety of ivermectin and doxycycline in combination or IVE ' 'alone in patients with COVID-19 infection ' 'clinicaltrials.gov/ct2/show/NCT04407130'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0101|cit101', 'unstructured': 'Efficacy, safety and tolerability of ivermectin in subjects infected ' 'with SARS-CoV-2 with or without symptoms ' 'clinicaltrials.gov/ct2/show/NCT04407507'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0102|cit102', 'unstructured': 'Evaluation of ivermectin mucoadhesive nanosuspension as nasal spray in ' 'management of early Covid-19 clinicaltrials.gov/ct2/show/NCT04716569'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0103|cit103', 'unstructured': 'Ivermectin Role In Covid-19 Clinical Trial (IRICT) ' 'clinicaltrials.gov/ct2/show/NCT04746365'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0104|cit104', 'unstructured': 'The Zambia Ivermectin Trial for the treatment and prevention of COVID-19 ' '(ZIT) clinicaltrials.gov/ct2/show/NCT04891250'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0105|cit105', 'unstructured': 'In vivo use of ivermectin (IVR) for treatment for corona virus infected ' 'patients: a randomized controlled trial ' 'chictr.org.cn/showprojen.aspx?proj=54707'}, { 'issue': '6', 'key': '10.1002/14651858.CD015017.pub2-BIB0106|cit106', 'doi-asserted-by': 'publisher', 'first-page': '989', 'DOI': '10.3390/v13060989', 'article-title': 'Effects of a single dose of ivermectin on viral and clinical outcomes ' 'in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in ' 'Lebanon', 'volume': '13', 'author': 'Samaha', 'year': '2021', 'journal-title': 'Viruses'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0107|cit107', 'unstructured': 'Study of the efficacy of ivermectin in the treatment and prevention of ' 'COVID-19 clinicaltrialsregister.eu/ctr-search/trial/2020-001994-66/ES'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0108|cit108', 'unstructured': 'A randomized double-blind placebo-controlled trial of oral ivermectin ' 'for outpatient treatment of those at high risk for hospitalization due ' 'to COVID-19 ' 'anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000982910'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0109|cit109', 'unstructured': 'A phase IIB open label randomized controlled trial to evaluate the ' 'efficacy and safety of ivermectin in reducing viral loads in patients ' 'with hematological disorders who are admitted with COVID 19 infection ' 'ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43449'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0110|cit110', 'unstructured': 'Study to efficacy of ivermectin in patients of COVID-19 ' 'ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=43728&EncHid=&modid=&compid=%27,%2743728det%27'}, { 'issue': '1', 'key': '10.1002/14651858.CD015017.pub2-BIB0111|cit111', 'doi-asserted-by': 'publisher', 'first-page': '262', 'DOI': '10.1186/s13063-021-05236-2', 'article-title': 'Randomized clinical trial to compare the efficacy of ivermectin versus ' 'placebo to negativize nasopharyngeal PCR in patients with early ' 'COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol ' 'for randomized controlled trial', 'volume': '22', 'author': 'Garcia', 'year': '2021', 'journal-title': 'Trials'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0112|cit112', 'unstructured': 'Garica PJ Huratdo HM Urgae-Gil C Leon P Malaga G Chaccour C Randomized ' 'clinical trial to compare the efficacy of ivermectin versus placebo to ' 'negativize\xa0nasopharyngeal PCR in patients with early COVID-19 in Peru ' '(SAINT-Peru): a structured\xa0summary of a study protocol for randomized ' 'controlled trial researchsquare.com/article/rs-345747/v1 ' '10.21203/rs.3.rs-345747/v1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0113|cit113', 'unstructured': 'Randomized phase IIA clinical trial to evaluate the efficacy of ' 'ivermectin to obtain negative PCR results in patients with early phase ' 'COVID-19 (SAINT-PERU) clinicaltrials.gov/ct2/show/NCT04635943'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0114|cit114', 'unstructured': 'Randomized phase IIa clinical trial to compare the efficacy of ' 'ivermectin versus placebo to obtain negative PCR results in patients ' 'with early phase Covid-19 ' 'www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=034-20'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0115|cit115', 'unstructured': 'Double-blind placebo-controlled clinical trial of evaluating the ' 'effectiveness of ivermectin in treatment of outpatients with COVID-19 in ' '2021 irct.ir/trial/53949'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0116|cit116', 'unstructured': 'Double-blind placebo-controlled clinical trial of evaluating the ' 'effectiveness of ivermectin in treatment of patients admitted with ' 'COVID-19 in 2021 en.irct.ir/trial/54402'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0117|cit117', 'unstructured': 'Evaluation effects of the standard regimen along with ivermectin on ' 'treatment of corona virus type 2 pneumonia irct.ir/trial/49280'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0118|cit118', 'unstructured': 'Evaluating the efficacy and safety of Ivermectin in the treatment of ' 'COVID-19 patients: a double-blind randomized controlled trial, phase II ' 'en.irct.ir/trial/49935'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0119|cit119', 'unstructured': 'Ivermectin as a novel therapy in COVID-19 treatment ' 'clinicaltrials.gov/ct2/show/NCT04403555'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0120|cit120', 'unstructured': 'Ivermectin in treatment of COVID 19 patients ' 'clinicaltrials.gov/ct2/show/NCT04425707'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0121|cit121', 'unstructured': 'Ivermectin vs. placebo for the treatment of patients with mild to ' 'moderate COVID-19 clinicaltrials.gov/ct2/show/NCT04429711'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0122|cit122', 'unstructured': 'Randomized, double-blind, multi centre phase II, proof of concept, dose ' 'finding clinical trial on ivermectin for the early treatment of COVID-19 ' 'clinicaltrialsregister.eu/ctr-search/trial/2020-002283-32/IT'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0123|cit123', 'unstructured': 'COVidIVERmectin: ivermectin for treatment of Covid-19 (COVER) ' 'clinicaltrials.gov/ct2/show/NCT04438850'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0124|cit124', 'unstructured': 'Ivermectin in treatment of COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04445311'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0125|cit125', 'unstructured': 'Efficacy of subcutaneous ivermectin with or without zinc in COVID-19 ' 'patients (SIZI-COVID-PK) clinicaltrials.gov/ct2/show/NCT04472585'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0126|cit126', 'unstructured': 'Ivermectin nasal spray for COVID19 patients ' 'clinicaltrials.gov/ct2/show/NCT04510233'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0127|cit127', 'unstructured': 'Effectiveness and safety of ivermectin for the prevention of Covid-19 ' 'infection in Colombian health personnel (IveprofCovid19) ' 'clinicaltrials.gov/ct2/show/NCT04527211'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0128|cit128', 'unstructured': 'Ivermectin in adults with severe COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04602507'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0129|cit129', 'unstructured': 'Evaluation of prognostic modification in COVID-19 patients in early ' 'intervention treatment, a randomized clinical trial ' 'clinicaltrials.gov/ct2/show/NCT04673214'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0130|cit130', 'unstructured': 'Double-blind study in Covid-19 patients with ivermectin ' 'jrct.niph.go.jp/en-latest-detail/jRCT2031200120'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0131|cit131', 'unstructured': 'Study in Covid-19 patients with ivermectin (CORVETTE-01) ' 'clinicaltrials.gov/ct2/show/NCT04703205'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0132|cit132', 'unstructured': 'The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial) ' 'https://clinicaltrials.gov/ct2/show/NCT04712279'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0133|cit133', 'unstructured': 'Repurposed approved therapies for outpatient treatment of patients with ' 'early-onset COVID-19 and mild symptoms ' 'clinicaltrials.gov/ct2/show/NCT04727424'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0134|cit134', 'unstructured': 'An outpatient clinical trial using ivermectin and doxycycline in ' 'COVID-19 positive patients at high risk to prevent COVID-19 related ' 'hospitalization clinicaltrials.gov/ct2/show/NCT04729140'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0135|cit135', 'unstructured': 'Efficacy of ivermectin in outpatients with non-severe COVID-19 ' 'clinicaltrials.gov/ct2/show/NCT04834115'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0136|cit136', 'unstructured': 'Clinical trial to "study the efficacy and therapeutic safety of ' 'ivermectin (SAINTBO) clinicaltrials.gov/ct2/show/NCT04836299'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0137|cit137', 'unstructured': 'ACTIV-6: COVID-19 study of repurposed medications ' 'clinicaltrials.gov/ct2/show/NCT04885530'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0138|cit138', 'unstructured': 'Ivermectina Colombia (IVERCOL) clinicaltrials.gov/ct2/show/NCT04886362'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0139|cit139', 'unstructured': 'Prophylaxis for COVID-19: ivermectin in close contacts of COVID-19 cases ' '(IVERNEX-TUC) clinicaltrials.gov/ct2/show/NCT04894721'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0140|cit140', 'unstructured': 'Ivermectin Treatment Trial (ITT) ' 'pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-PACTR202102588777597'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0141|cit141', 'unstructured': 'Double blind, community-based, randomized controlled trial on the use of ' 'ivermectin as post exposure chemo-prophylaxis for COVID-19 among high ' 'risk individuals in Lagos (IVERPEPCOV) COVID-19 ' 'pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-PACTR202102848675636'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0142|cit142', 'unstructured': 'Ivermectin to prevent hospitalizations in COVID-19 (IVERCORCOVID19) ' 'clinicaltrials.gov/ct2/show/NCT04529525'}, { 'issue': '1', 'key': '10.1002/14651858.CD015017.pub2-BIB0143|cit143', 'doi-asserted-by': 'publisher', 'first-page': '965', 'DOI': '10.1186/s13063-020-04813-1', 'article-title': 'Ivermectin to prevent hospitalizations in patients with COVID-19 ' '(IVERCOR-COVID19): a structured summary of a study protocol for a ' 'randomized controlled trial', 'volume': '21', 'author': 'Vallejos', 'year': '2020', 'journal-title': 'Trials'}, { 'issue': '2', 'key': '10.1002/14651858.CD015017.pub2-BIB0144|cit144', 'doi-asserted-by': 'publisher', 'first-page': '134', 'DOI': '10.1016/j.ijantimicag.2019.05.003', 'article-title': 'Ivermectin: from theory to clinical application', 'volume': '54', 'author': 'Ashour', 'year': '2019', 'journal-title': 'International Journal of Antimicrobial Agents'}, { 'issue': '4', 'key': '10.1002/14651858.CD015017.pub2-BIB0145|cit145', 'doi-asserted-by': 'crossref', 'first-page': '401', 'DOI': '10.1016/j.jclinepi.2010.07.015', 'article-title': 'GRADE guidelines - 3: rating the quality of evidence', 'volume': '64', 'author': 'Balshem', 'year': '2011', 'journal-title': 'Journal of Clinical Epidemiology'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0146|cit146', 'doi-asserted-by': 'publisher', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'article-title': 'Remdesivir for the treatment of Covid-19 - final report', 'volume': '383', 'author': 'Beigel', 'year': '2020', 'journal-title': 'New England Journal of Medicine'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0147|cit147', 'unstructured': 'British Ivermectin Recommendation Development panel The BIRD ' 'recommendation on the use of ivermectin for Covid-19 ' 'francesoir.fr/sites/francesoir/files/media-icons/bird-proceedings-02-03-2021-v151.pdf'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0148|cit148', 'unstructured': 'Bryant A Lawrie T Dowswell T \xa0Fordham E Mitchell S Hill S Ivermectin ' 'for prevention and treatment of COVID-19 infection American Journal of ' 'Therapeutics 10.1097/MJT.0000000000001402'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0149|cit149', 'doi-asserted-by': 'publisher', 'first-page': 'e1047874', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Research'}, { 'issue': '4613', 'key': '10.1002/14651858.CD015017.pub2-BIB0150|cit150', 'doi-asserted-by': 'publisher', 'first-page': '823', 'DOI': '10.1126/science.6308762', 'article-title': 'Ivermectin: a potent new antiparasitic agent', 'volume': '221', 'author': 'Campbell', 'year': '1983', 'journal-title': 'Science'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0151|cit151', 'unstructured': 'Cochrane LSR Guidance for the production and publication of Cochrane ' 'living systematic reviews: Cochrane Reviews in living mode Available ' 'from ' 'community.cochrane.org/review-production/production-resources/living-systematic-reviews'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0152|cit152', 'doi-asserted-by': 'crossref', 'first-page': '18', 'DOI': '10.1186/1741-7015-8-18', 'article-title': '\xa0CONSORT 2010 Statement: updated guidelines for reporting parallel ' 'group randomised trials', 'volume': '8', 'author': 'Schulz', 'journal-title': 'BMC Medicine'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0153|cit153', 'unstructured': 'Covid Management Guidelines India Group COVID Management Guidelines ' 'India indiacovidguidelines.org/ivermectin/'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0154|cit154', 'unstructured': 'COVID-NMA working group The COVID-NMA initiative: a living mapping and ' 'living systematic review of Covid-19 trials covid-nma.com'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0155|cit155', 'unstructured': 'Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking ' 'meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, ' 'Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of ' 'Interventions version 6.1 (updated September 2020). Cochrane Available ' 'from training.cochrane.org/handbook/archive/v6.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0156|cit156', 'doi-asserted-by': 'publisher', 'first-page': 'e179', 'DOI': '10.1186/s13054-020-02902-w', 'article-title': 'Clinical determinants for fatality of 44,672 patients with COVID-19', 'volume': '24', 'author': 'Deng', 'year': '2020', 'journal-title': 'Critical Care'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0157|cit157', 'doi-asserted-by': 'crossref', 'unstructured': 'Dong E Du H Gardner L An interactive web-based dashboard to track ' 'COVID-19 in real time Lancet Infectious Diseases 2020 20 5 533 4 ' '10.1016/S1473-3099(20)30120-1', 'DOI': '10.1016/S1473-3099(20)30120-1'}, { 'issue': '12', 'key': '10.1002/14651858.CD015017.pub2-BIB0158|cit158', 'doi-asserted-by': 'publisher', 'first-page': '981', 'DOI': '10.1111/j.1365-4632.2004.02253.x', 'article-title': 'Ivermectin: pharmacology and application in dermatology', 'volume': '44', 'author': 'Dourmishev', 'year': '2005', 'journal-title': 'International Journal of Dermatology'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0159|cit159', 'unstructured': 'European Medicines Agency EMA advises against use of ivermectin for the ' 'prevention or treatment of COVID-19 outside randomised clinical trials ' 'ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0160|cit160', 'unstructured': 'Product safety information: COVID-19 and ivermectin intended for animals ' 'fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-ivermectin-intended-animals'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0161|cit161', 'unstructured': 'Garegnani LI Madrid E Meza N Misleading clinical evidence and systematic ' 'reviews on ivermectin for COVID-19 BMJ Evidence Based Medicine ' '10.1136/bmjebm-2021-111678 33888547'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0162|cit162', 'unstructured': 'Kluge S Janssens U Weber-Carstens S Schälte G Spinner CD S3-Guideline - ' 'recommendations on Inpatient Treatment of Patients With COVID-19 ' 'awmf.org/uploads/tx_szleitlinien/113-001l_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19__2021-02.pdf'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0163|cit163', 'doi-asserted-by': 'publisher', 'first-page': 'e23138', 'DOI': '10.1038/srep23138', 'article-title': 'Influenza A viruses escape from MxA restriction at the expense of ' 'efficient nuclear vRNP import', 'volume': '6', 'author': 'Dornfeld', 'year': '2016', 'journal-title': 'Scientific Reports'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0164|cit164', 'doi-asserted-by': 'publisher', 'first-page': '42', 'DOI': '10.1208/s12248-007-9000-9', 'article-title': 'The pharmacokinetics and interactions of ivermectin in humans', 'volume': '10', 'author': 'González-Canga', 'year': '2008', 'journal-title': 'Journal of the American Association of Pharmaceutical Scientists'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0165|cit165', 'doi-asserted-by': 'crossref', 'first-page': '599533', 'DOI': '10.3389/fmed.2020.599533', 'article-title': 'COVID-19 induced acute respiratory distress syndrome - a multicenter ' 'observational study', 'volume': '7', 'author': 'Herrmann', 'year': '2020', 'journal-title': 'Frontiers in Medicine'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0166|cit166', 'unstructured': 'Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook ' 'for Systematic Reviews of Interventions version 6.1 (updated September ' '2020). Cochrane, 2020 Available from ' 'training.cochrane.org/handbook/archive/v6.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0167|cit167', 'unstructured': 'Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized ' 'trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, ' 'et al, editor(s). Cochrane Handbook for Systematic Reviews of ' 'Interventions version 6.1 (updated September 2020). Cochrane, 2020 ' 'Available from training.cochrane.org/handbook/archive/v6.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0168|cit168', 'unstructured': 'Higgins JP Savović J Page MJ Elbers RG Sterne JA Chapter 8: Assessing ' 'risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler ' 'J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for ' 'Systematic Reviews of Interventions version 6.1 (updated September ' '2020). Cochrane, 2020 Available from ' 'training.cochrane.org/handbook/archive/v6.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0169|cit169', 'unstructured': 'Higgins JP Li T Chapter 6: Choosing effect measures and computing ' 'estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, ' 'Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic ' 'Reviews of Interventions version 6.1 (updated September 2020). Cochrane, ' '2020 Available from training.cochrane.org/handbook/archive/v6.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0170|cit170', 'unstructured': 'Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E ' 'Methodological Expectations of Cochrane Intervention Reviews. Cochrane: ' 'London, Version February 2021 Available from: ' 'www.community.cochrane.org/mecir-manual/'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0171|cit171', 'unstructured': 'Hill A Abdulamir A Ahmed S Ashgar A Basri E Meta-analysis of randomized ' 'trials of ivermectin to treat SARS-CoV-2 infection ' 'researchsquare.com/article/rs-148845/v1 10.21203/rs.3.rs-148845/v1'}, { 'issue': '10223', 'key': '10.1002/14651858.CD015017.pub2-BIB0172|cit172', 'doi-asserted-by': 'publisher', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'volume': '395', 'author': 'Huang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0173|cit173', 'unstructured': 'Bhimraj A Morgan RL Shumaker AH Lavergne V Baden L Cheng VC Infectious ' 'Diseases Society of America guidelines on the treatment and management ' 'of patients with COVID-19, version 4.3.0 ' 'idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/'}, { 'issue': '6', 'key': '10.1002/14651858.CD015017.pub2-BIB0174|cit174', 'doi-asserted-by': 'publisher', 'first-page': 'e010247', 'DOI': '10.1136/bmjopen-2015-010247', 'article-title': 'Plea for routinely presenting prediction intervals in meta-analysis', 'volume': '12', 'author': 'IntHout', 'year': '2016', 'journal-title': 'BMJ Open'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0175|cit175', 'unstructured': 'Ivermectin for COVID-19: real-time meta analysis of 60 studies ' 'ivmmeta.com/'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0176|cit176', 'doi-asserted-by': 'publisher', 'first-page': '853', 'DOI': '10.1016/S2213-2600(20)30316-7', 'article-title': 'Case characteristics, resource use, and outcomes of 10\u2008021 ' 'patients with COVID-19 admitted to 920 German hospitals: an ' 'observational study', 'volume': '9', 'author': 'Karagiannidis', 'year': '2020', 'journal-title': 'Lancet Respiratory Medicine'}, { 'issue': '2', 'key': '10.1002/14651858.CD015017.pub2-BIB0177|cit177', 'doi-asserted-by': 'publisher', 'first-page': '580', 'DOI': '10.3390/jcm9020580', 'article-title': 'Communicating the risk of death from novel coronavirus disease ' '(COVID-19)', 'volume': '9', 'author': 'Kobayashi', 'year': '2020', 'journal-title': 'Journal of\xa0Clinical Medicine'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0178|cit178', 'unstructured': 'Kory P Meduri GU Iglesias J Varon J Berkowitz K Kornfeld H Review of the ' 'emerging evidence demonstrating the efficacy of ivermectin in the ' 'prophylaxis and treatment of COVID-19 osf.io/wx3zn/ ' '10.31219/osf.io/wx3zn'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0179|cit179', 'unstructured': 'Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI ' 'Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas ' 'J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane ' 'Handbook for Systematic Reviews of Interventions version 6.1 (updated ' 'September 2020). Cochrane, 2020 Available from: ' 'training.cochrane.org/handbook/archive/v6.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0180|cit180', 'unstructured': 'MAGICapp MAGIC 2020'}, { 'issue': '8', 'key': '10.1002/14651858.CD015017.pub2-BIB0181|cit181', 'doi-asserted-by': 'publisher', 'first-page': 'e192', 'DOI': '10.1016/S1473-3099(20)30483-7', 'article-title': 'A minimal common outcome measure set for COVID-19 clinical research', 'volume': '20', 'author': 'Marshall', 'year': '2020', 'journal-title': 'Lancet Infectious Diseases'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0182|cit182', 'unstructured': 'Merck statement on ivermectin use during the COVID-19 pandemic ' 'merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0183|cit183', 'unstructured': 'cran.r-project.org/web/packages/meta Meta: general package for ' 'meta-analysis 2021'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0184|cit184', 'unstructured': 'COVID-19 treatment guidelines panel Coronavirus disease 2019 (COVID-19) ' 'treatment guidelines www.covid19treatmentguidelines.nih.gov/'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0185|cit185', 'doi-asserted-by': 'crossref', 'unstructured': 'Oran DP The proportion of SARS-CoV-2 infections that are asymptomatic: a ' 'systematic review Annals of Internal Medicine 2021 174 5 655 62 ' '10.7326/M20-6976', 'DOI': '10.7326/M20-6976'}, { 'issue': '1', 'key': '10.1002/14651858.CD015017.pub2-BIB0186|cit186', 'first-page': '11', 'article-title': 'The efficacy of topical and oral ivermectin in the treatment of human ' 'scabies', 'volume': '61', 'author': 'Panahi', 'year': '2015', 'journal-title': 'Annals of Parasitology'}, { 'issue': '8', 'key': '10.1002/14651858.CD015017.pub2-BIB0187|cit187', 'doi-asserted-by': 'publisher', 'first-page': '739', 'DOI': '10.1001/jama.2020.14103', 'article-title': 'Recovery from severe COVID-19', 'volume': '324', 'author': 'Prescott', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0188|cit188', 'unstructured': 'University of Oxford Ivermectin to be investigated in adults aged 18+ as ' 'a possible treatment for COVID-19 in the PRINCIPLE trial ' 'principletrial.org/news/ivermectin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-oxford2019s-principle-trial'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0189|cit189', 'doi-asserted-by': 'publisher', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'article-title': 'Dexamethasone in hospitalized patients with Covid-19', 'volume': '384', 'author': 'Recovery Collaborative Group', 'year': '2021', 'journal-title': 'New England Journal of Medicine'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0190|cit190', 'unstructured': 'Review Manager Web (RevMan Web) Cochrane 2020'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0191|cit191', 'doi-asserted-by': 'publisher', 'first-page': '481', 'DOI': '10.1038/d41586-020-02958-2', 'article-title': "Latin America's embrace of an unproven COVID treatment is hindering " 'drug trials', 'volume': '586', 'author': 'Rodríguez-Mega', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0192|cit192', 'unstructured': 'Schünemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: ' 'Completing ‘Summary of findings’ tables and grading the certainty of the ' 'evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page ' 'MJ, et al (editors). Cochrane Handbook for Systematic Reviews of ' 'Interventions version 6.1 (updated September 2020). Cochrane, 2020 ' 'Available from training.cochrane.org/handbook/archive/v6.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0193|cit193', 'doi-asserted-by': 'publisher', 'first-page': 'm379', 'DOI': '10.1136/bmj.m3379', 'article-title': 'A living WHO guideline on drugs for Covid-19', 'volume': '370', 'author': 'Siemieniuk', 'year': '2020', 'journal-title': 'BMJ'}, { 'issue': '2', 'key': '10.1002/14651858.CD015017.pub2-BIB0194|cit194', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/14651858.CD013587.pub2', 'article-title': 'Chloroquine or hydroxychloroquine for prevention and treatment of ' 'COVID-19', 'author': 'Singh', 'year': '2021', 'journal-title': 'Cochrane Database of Systematic Reviews'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0195|cit195', 'doi-asserted-by': 'publisher', 'first-page': 'l4898', 'DOI': '10.1136/bmj.l4898', 'article-title': 'RoB 2: a revised tool for assessing risk of bias in randomised trials', 'volume': '366', 'author': 'Sterne', 'year': '2019', 'journal-title': 'BMJ'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0196|cit196', 'unstructured': 'Weibel S Popp M Supplementary File_Ivermectin_Risk of Bias Excel Tool ' '(Version 1) Zenodo 2021 10.5281/zenodo.5118956'}, { 'issue': '3', 'key': '10.1002/14651858.CD015017.pub2-BIB0197|cit197', 'doi-asserted-by': 'publisher', 'first-page': '301', 'DOI': '10.1016/j.antiviral.2013.06.002', 'article-title': 'Nuclear localization of dengue virus (DENV) 1-4 non-structural protein ' '5; protection against all 4 DENV serotypes by the inhibitor Ivermectin', 'volume': '99', 'author': 'Fraser', 'year': '2013', 'journal-title': 'Antiviral Research'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0198|cit198', 'unstructured': 'Davey M Huge study supporting ivermectin as Covid treatment withdrawn ' 'over ethical concerns Available at ' 'www.theguardian.com/science/2021/jul/16/huge-study-supporting-ivermectin-as-covid-treatment-withdrawn-over-ethical-concerns'}, { 'issue': '3', 'key': '10.1002/14651858.CD015017.pub2-BIB0199|cit199', 'doi-asserted-by': 'publisher', 'first-page': '851', 'DOI': '10.1042/BJ20120150', 'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear ' 'import able to inhibit replication of HIV-1 and dengue virus', 'volume': '443', 'author': 'Heaton', 'year': '2012', 'journal-title': 'Biochemical Journal'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0200|cit200', 'doi-asserted-by': 'publisher', 'first-page': 'm1808', 'DOI': '10.1136/bmj.m1808', 'article-title': 'Interpreting a Covid-19 test result', 'volume': '369', 'author': 'Watson', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0201|cit201', 'unstructured': 'World Health Organization The World Health Organization Quality of Life ' '(WHOQOL) www.who.int/publications/i/item/WHO-HIS-HSI-Rev.2012.03'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0202|cit202', 'unstructured': 'World Health Organization WHO model list of essential medicines, 21st ' 'list www.who.int/medicines/publications/essentialmedicines/en'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0203|cit203', 'unstructured': 'World Health Organization Report of the WHO-China Joint Mission on ' 'Coronavirus Disease 2019 (COVID-19) ' 'www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0204|cit204', 'unstructured': 'World Health Organization WHO coronavirus disease (COVID-19) dashboard ' 'covid19.who.int/'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0205|cit205', 'unstructured': 'World Health Organization Antigen-detection in the diagnosis of ' 'SARS-CoV-2 infection using rapid immunoassays: interim guidance, 11 ' 'September 2020 Available at ' 'https://apps.who.int/iris/handle/10665/334253'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0206|cit206', 'unstructured': 'World Health Organization Weekly epidemiological update - 19 January ' '2021 ' 'www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0207|cit207', 'unstructured': 'World Health Organization Therapeutics and COVID-19. Living guideline ' 'who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0208|cit208', 'doi-asserted-by': 'publisher', 'first-page': '430', 'DOI': '10.1038/s41586-020-2521-4', 'article-title': 'Factors associated with COVID-19-related death using OpenSAFELY', 'volume': '584', 'author': 'Williamson', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0209|cit209', 'doi-asserted-by': 'publisher', 'first-page': 'e553', 'DOI': '10.3389/fmicb.2015.00553', 'article-title': 'Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA ' 'viruses', 'volume': '6', 'author': 'Wulan', 'year': '2015', 'journal-title': 'Frontiers in Microbiology'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0210|cit210', 'unstructured': 'Yamasmith E Saleh-arong FA Avirutnan P Mairiang D Wongsawat E Efficacy ' 'and safety of ivermectin against dengue infection: a phase III, ' 'randomized, double-blind, placebo-controlled trial Internal Medicine and ' 'One Health. 34th Annual Meeting of the Royal College of Physicians of ' 'Thailand; 2018 April 26-28; Chonburi (THA) 2018'}, { 'key': '10.1002/14651858.CD015017.pub2-BIB0211|cit211', 'doi-asserted-by': 'publisher', 'first-page': 'e104760', 'DOI': '10.1016/j.antiviral.2020.104760', 'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer', 'volume': '177', 'author': 'Yang', 'year': '2020', 'journal-title': 'Antiviral Research'}, { 'issue': '4', 'key': '10.1002/14651858.CD015017.pub2-BIB0212|cit212', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/14651858.CD015017', 'article-title': 'Ivermectin for preventing and treating COVID-19', 'author': 'Popp', 'year': '2021', 'journal-title': 'Cochrane Database of Systematic Reviews'}], 'container-title': 'Cochrane Database of Systematic Reviews', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2022, 5, 31]], 'date-time': '2022-05-31T11:51:57Z', 'timestamp': 1653997917000}, 'score': 1, 'resource': {'primary': {'URL': 'http://doi.wiley.com/10.1002/14651858.CD015017.pub2'}}, 'subtitle': [], 'editor': [ {'name': 'Cochrane Infectious Diseases Group', 'sequence': 'first', 'affiliation': []}, {'name': 'Cochrane Haematology Group', 'sequence': 'additional', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2021, 7, 28]]}, 'references-count': 212, 'journal-issue': {'issue': '10', 'published-online': {'date-parts': [[2021, 10]]}}, 'URL': 'http://dx.doi.org/10.1002/14651858.CD015017.pub2', 'relation': {}, 'ISSN': ['1465-1858'], 'subject': [], 'published': {'date-parts': [[2021, 7, 28]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit